A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)
Status:
Completed
Trial end date:
2019-07-18
Target enrollment:
Participant gender:
Summary
This study is conducted to evaluate the safety of intravitreal THR-317 administered in
combination with ranibizumab, and to assess the efficacy of the combination treatment in
improving best-corrected visual acuity (BCVA) and reducing central subfield thickness (CST),
in subjects with central-involved diabetic macular oedema (CI-DME).